Search details
1.
Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.
BMC Cancer
; 23(1): 554, 2023 Jun 16.
Article
in English
| MEDLINE | ID: mdl-37328818
2.
Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.
Support Care Cancer
; 30(8): 6583-6591, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35484315
3.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 22(4): 463-475, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33684370
4.
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
N Engl J Med
; 379(5): 417-427, 2018 Aug 02.
Article
in English
| MEDLINE | ID: mdl-29860937
5.
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Lancet Oncol
; 21(9): 1173-1187, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32758455
6.
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Lancet Oncol
; 15(13): 1442-1450, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25456363
7.
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Eur J Cancer
; 201: 113589, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38382153
8.
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
Eur J Cancer
; 193: 113292, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37717282
9.
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
J Immunother Cancer
; 11(11)2023 11.
Article
in English
| MEDLINE | ID: mdl-37935564
10.
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Eur Urol Oncol
; 2023 Oct 07.
Article
in English
| MEDLINE | ID: mdl-37813745
11.
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Eur J Cancer
; 182: 66-76, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36746010
12.
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Eur J Cancer
; 183: 24-37, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36796234
13.
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
J Clin Oncol
; 41(25): 4107-4117, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37369081
14.
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Lancet Oncol
; 12(7): 673-80, 2011 Jul.
Article
in English
| MEDLINE | ID: mdl-21664867
15.
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Eur Urol Oncol
; 5(5): 577-584, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35853818
16.
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Clin Genitourin Cancer
; 20(5): 488-494, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35977881
17.
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.
Eur J Cancer
; 173: 105-112, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35863105
18.
Factors associated with under-reporting of head and neck squamous cell carcinoma in cause-of-death records: A comparative study of two national databases in France from 2008 to 2012.
PLoS One
; 16(2): e0246252, 2021.
Article
in English
| MEDLINE | ID: mdl-33534860
19.
Expression of immune response biomarkers (PDL1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
Oncol Rep
; 45(3): 1273-1283, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33432367
20.
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
Eur J Cancer
; 142: 102-111, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33253997